Supernus Pharmaceuticals, Inc. (SUPN)

49.70 -0.19 (-0.38%) USD  |  NASDAQ  |  Dec 31, 16:00
49.67 -0.03 (-0.06%) After-Hours: 20:00
More

Supernus Pharmaceuticals Research and Development Expense (TTM): 104.86M for Sept. 30, 2025

Research and Development Expense (TTM) Chart

View Research and Development Expense (TTM) for SUPN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (TTM) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (TTM) Range, Past 5 Years

View Research and Development Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (TTM) Benchmarks

View Research and Development Expense (TTM) Benchmarks
Start Trial
BridgeBio Pharma, Inc. 465.89M
The Cooper Cos., Inc. 172.20M
Assembly Biosciences, Inc. 61.75M
Amphastar Pharmaceuticals, Inc. 66.60M
Viking Therapeutics, Inc. 222.48M